Endothelin a receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7453-7464

  Rosanò, Laura ^a   Cianfrocca, Roberta ^a   Tocci, Piera ^a   Spinella, Francesca ^a   Di Castro, Valeriana ^a   Caprara, Valentina ^a   Semprucci, Elisa ^a   Ferrandina, Gabriella ^b   Natali, Pier Giorgio ^a,c   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BETA CATENIN; CISPLATIN; E1A ASSOCIATED P300 PROTEIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; MACITENTAN; PACLITAXEL; WNT PROTEIN; ZIBOTENTAN; RETINA S ANTIGEN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL INVASION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN REORGANIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; ET 1 GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME; DRUG RESISTANCE; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ARRESTINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOTHELIN-1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, ENDOTHELIN A; WNT SIGNALING PATHWAY;

EID: 84918530212     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3133     Document Type: Article

References (45)

1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
2. Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2013;13:637-51.
3. Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets 2012;13:1649-53.
4. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2013;49:520-30.
5. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10:47-60.
6. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMTphenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011;17:2350-60.
7. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005;65:11649-57.
8. Jazaeri AA, Awtrey CS, Chandramouli GV, Awtrey CS, Chandramouli GV, Chuang YE, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-10.
9. Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 2010;117:170-6.
10. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008;14:28-36.
11. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009;15:4521-8.
12. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703-11.
13. Spinella F, Garrafa E, Di Castro V, Rosanò L, Nicotra MR, Caruso A, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 2009;69:2669-76.
14. Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of Paclitaxel by modulating survival pathways in orthototic models of metastatic human ovarian cancer. Neoplasia 2011;13:167-79.
15. Kim SJ, Kim JS, Kim SW, Yun SJ, He J, Brantley E, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol 2012;5:39-47.
16. Shenoy SK, Lefkowitz RJ. β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 2011;32:521-33.
17. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2009;106:2806-11.
18. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, et al. β-Arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 2013;32:5066-77.
19. Spinella F, Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG, et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med 2013;91:395-405.
20. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suárez A, Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527-36.
21. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, et al. Beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 2003;88:363-8.
22. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. Oncogene 2013;32:2767-81.
23. Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol 2013;131:772-9.
24. Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, et al. The discovery of N-[5-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy-]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptorantagonist. J Med Chem 2012;55:7849-61.
25. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et al. Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45.
26. Hoeppner CZ, Cheng N, Ye RD. Identification of a nuclear localization sequence in b-arrestin-1 and its functional implications. J Biol Chem 2012;287:8932-43.
27. Yang M, He RL, Benovic JL, Ye RD. Beta-arrestin1 interacts with the G-protein subunits beta1gamma2 and promotes beta1gamma2-dependent Akt signaling for NF-kappaB activation. Biochem J 2009;417:287-96.
28. Schuijers J, Mokry M, Hatzis P, Cuppen E, Clevers H. Wnt-induced transcriptional activation is exclusively mediated by TCF/LEF. EMBOJ 2014;33:146-56.
29. Kim TH, Xiong H, Zhang Z, Ren B. Beta-catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 2005;24:597-604.
30. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 2011;11:22850-64.
31. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010;10:268-78.
32. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
33. Coffman L, Mooney C, Lim J, Bai S, Silva I, Gong Y, et al. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther 2013;14:184-92.
34. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A 2013;110:9845-50.
35. Adham SA, Sher I, Coomber BL. Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab Invest 2010;90:709-23.
36. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosanò L, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002;61:524-32.
37. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014;26:77-91.
38. Sun P, Xiong H, Kim T H, Ren B, Zhang Z. Positive inter-regulation between β-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells. Mol Pharmacol 2006;69:520-31.
39. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004;10:1032-42.
40. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, et al. Epithelial ovarian cancer experimental models. Oncogene 2014;33:3619-33.
41. Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, et al. A phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecol Oncol 2013;130:31-7.
42. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 2011;121:132-47.
43. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 2012;91:528-39.
44. Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev 2014;33:17-39.
45. Kim SW, Chai HJ, Lee H-J, He J, Wu Q, Langley RR, et al. Role of endotheln axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro-Oncology 2014;0:1-14.